FEATURED

GI Cancers Symposium 2017

Ongoing coverage of the 2017 Gastrointestinal (GI) Cancers Symposium in San Francisco.

Novel Targeted Agents For First-line CLL

Research is needed to determine which targeted agents should be used in young, fit patients and elderly unfit patients, and which regimens should be used first.

Case Study: 59-year-old With GIST

M.T., a 59-year-old female patient with unresectable malignant gastric gastrointestinal stromal tumor (GIST) presents to discuss treatment options.

SN-MMR for Stratification of SNB-positive Melanoma

SN-MMR was strongly associated with OS, melanoma-specific survival, and DFS among patients with a positive sentinel node biopsy.

Radiogenomics: Biomarkers for PCa RT Outcomes

Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.

Ponatinib: Black Box Warning, Drug Interactions

If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.

Metastatic PCa to the GI Tract

Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.

MGUS: Determining Significance in Multiple Myeloma

MGUS may progress to multiple myeloma, AL amyloidosis, Waldenstrom's macroglobulinemia, or lymphoma. But not all cases progress to malignancy.

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

New Video Series: Classical Hodgkin Lymphoma

Steven M. Ansell, MD, PhD, of the Mayo Clinic in Rochester, Minnesota

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Novel Targeted Agents For First-line CLL Treatment

Novel Targeted Agents For First-line CLL Treatment

Research is needed to determine which targeted agents should be used in young, fit patients and elderly unfit patients, and which regimens should be used first.

SN-MMR for Stratification of SNB-positive Melanoma

SN-MMR for Stratification of SNB-positive Melanoma

SN-MMR was strongly associated with OS, melanoma-specific survival, and DFS among patients with a positive sentinel node biopsy.

Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.

Ponatinib: Black Box Warning and Drug Interactions

Ponatinib: Black Box Warning and Drug Interactions

If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.

Metastatic Prostate Cancer to the Gastrointestinal Tract

Metastatic Prostate Cancer to the Gastrointestinal Tract

Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters